Overview

Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:
0

Participant gender:
All

Summary

The duration of sensory block after single dose of long acting local anesthetics is not sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. To the best of our knowledge, the use of Dexmedetomidine in different dose levels as adjuvant to local anesthetic was not previously reported for femoral nerve block.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Cairo University

Treatments:

Bupivacaine
Dexmedetomidine

Criteria

Inclusion Criteria:

- all patients with ASA physical status I or II, scheduled for arthroscopic knee surgery

Exclusion Criteria:

- Patients who are refusing regional block, patients with diabetic peripheral
neuropathy, renal or hepatic dysfunction, inflammation or infection at the puncture
site, and history of allergic reaction to study medications